12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Company News  |  Deals

Myriad Genetics, Tesaro deal

Tesaro will use Myriad's BRACAnalysis test to select patients likely to respond to the Tesaro's niraparib for enrollment in two Phase III trials of the poly(ADP-ribose) polymerase (PARP) inhibitor. Myriad markets BRACAnalysis to assess a woman's risk of developing breast or ovarian cancer based on...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >